PhRMA Clinical Trial Code: Disclosure Edition
Executive Summary
The Pharmaceutical Research and Manufacturers of America is committing its members to disclose a broader array of clinical trials as a means to defend the corporate-sponsored clinical development process against continuing charges of bias and against the erosion of public trust
You may also be interested in...
NIH Trials Registry Growing Quickly; Global Standards Up For Discussion
The federal clinical trials registry is growing at a 20 to 40 percent faster clip as a result of the FDA Amendments Act provision expanding the universe of trials subject to public listing requirements
GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005
The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.